Plasma monocyte chemoattractant protein-1 and the risk of kidney and cardiovascular outcomes in people with chronic kidney disease: results from the BRIGHTEN study

In patients with CKD, higher plasma MCP-1 levels are associated with a more rapid decline in kidney function but not with the composite outcome of kidney failure. MCP-1 was not associated with cardiovascular outcomes or mortality in this population cohort.